{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=23", "query": { "condition": "Melanoma", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 2274, "total_pages": 228, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:24:34.819Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01011530", "title": "Dose Escalation Study of MLN4924 in Adults With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "MLN4924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2009-12", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-07-16", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011530" }, { "nct_id": "NCT00257465", "title": "Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Autologous, DNP-modified vaccine (M-Vax)", "type": "BIOLOGICAL" }, { "name": "Autologous, DNP-Modified Melanoma Vaccine", "type": "BIOLOGICAL" }, { "name": "Autologous, DNP-Modified Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AVAX Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2005-06", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 7, "location_summary": "Tucson, Arizona • San Diego, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00257465" }, { "nct_id": "NCT00073892", "title": "PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PI-88", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellxpert Biotechnology Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 44, "start_date": "2004-01", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2022-06-27", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073892" }, { "nct_id": "NCT02142335", "title": "Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Melanoma of Skin Stage III", "Metastatic Melanoma" ], "interventions": [ { "name": "Rituxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Assocaties for Research & Excellence", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2014-03", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 1, "location_summary": "Encinitas, California", "locations": [ { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142335" }, { "nct_id": "NCT04511013", "title": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Metastatic Mucosal Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-01-06", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 331, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 234 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511013" }, { "nct_id": "NCT01918930", "title": "Tissue Procurement Substudy for Participants in Study CP-MGA271-01", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-07", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 7, "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01918930" }, { "nct_id": "NCT06831071", "title": "Evaluation of Hypoxia in Primary Melanoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pimonidazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yana Najjar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-04-09", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06831071" }, { "nct_id": "NCT02012699", "title": "Integrated Cancer Repository for Cancer Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer", "Thyroid Cancer", "Lung Cancer", "Esophageal Cancer", "Thymus Cancer", "Colon Cancer", "Rectal Cancer", "Gastrointestinal Stromal Tumors", "Anal Cancer", "Bile Duct Cancer", "Duodenal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Liver Cancer", "Small Intestine Cancer", "Peritoneal Surface Malignancies", "Familial Adenomatous Polyposis", "Lynch Syndrome", "Bladder Cancer", "Kidney Cancer", "Penile Cancer", "Prostate Cancer", "Testicular Cancer", "Ureter Cancer", "Urethral Cancer", "Hypopharyngeal Cancer", "Laryngeal Cancer", "Lip Cancer", "Oral Cavity Cancer", "Nasopharyngeal Cancer", "Oropharyngeal Cancer", "Paranasal Sinus Cancer", "Nasal Cavity Cancer", "Salivary Gland Cancer", "Skin Cancer", "Central Nervous System Tumor", "Central Nervous System Cancer", "Mesothelioma", "Breast Cancer", "Leukemia", "Melanoma", "Sarcoma", "Unknown Primary Tumor", "Multiple Myeloma", "Ovarian Cancer", "Endometrial Cancer", "Vaginal Cancer", "Neuroendocrine Tumors", "Plasma Cell Dyscrasia", "Healthy Control" ], "interventions": [], "intervention_types": [], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "19 Years to 110 Years" }, "enrollment_count": 999999, "start_date": "2013-11-01", "completion_date": "2099-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 42, "location_summary": "Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more", "locations": [ { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012699" }, { "nct_id": "NCT07136181", "title": "Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Uveal Melanoma, Metastatic", "Uveal Melanoma, Recurrent", "Eye Cancer, Intraocular Melanoma", "Eye Cancer" ], "interventions": [ { "name": "NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelwise Pharmaceutical Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-11-20", "completion_date": "2029-08-30", "has_results": false, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07136181" }, { "nct_id": "NCT03698019", "title": "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acral Lentiginous Melanoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Mucosal Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2019-02-15", "completion_date": "2026-10-30", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-24T00:24:34.819Z", "location_count": 815, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698019" } ] }